Literature DB >> 11092114

Codeine analgesia is due to codeine-6-glucuronide, not morphine.

T B Vree1, R T van Dongen, P M Koopman-Kimenai.   

Abstract

Eighty per cent of codeine is conjugated with glucuronic acid to codeine-6-glucuronide. Only 5% of the dose is O-demethylated to morphine, which in turn is immediately glucuronidated at the 3- and 6-position and excreted renally. Based on the structural requirement of the opiate molecule for interaction with the mu-receptor to result in analgesia, codeine-6-glucuronide in analogy to morphine-6-glucuronide must be the active constituent of codeine. Poor metabolisers of codeine, those who lack the CYP450 2D6 isoenzyme for the O-demethylation to morphine, experience analgesia from codeine-6-glucuronide. Analgesia of codeine does not depend on the formation of morphine and the metaboliser phenotype.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11092114

Source DB:  PubMed          Journal:  Int J Clin Pract        ISSN: 1368-5031            Impact factor:   2.503


  16 in total

Review 1.  First-pass metabolism via UDP-glucuronosyltransferase: a barrier to oral bioavailability of phenolics.

Authors:  Baojian Wu; Kaustubh Kulkarni; Sumit Basu; Shuxing Zhang; Ming Hu
Journal:  J Pharm Sci       Date:  2011-04-11       Impact factor: 3.534

Review 2.  The Noscapine Chronicle: A Pharmaco-Historic Biography of the Opiate Alkaloid Family and its Clinical Applications.

Authors:  Padmashree C G Rida; Dillon LiVecche; Angela Ogden; Jun Zhou; Ritu Aneja
Journal:  Med Res Rev       Date:  2015-07-14       Impact factor: 12.944

Review 3.  Drug interactions with patient-controlled analgesia.

Authors:  Jorn Lotsch; Carsten Skarke; Irmgard Tegeder; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2002       Impact factor: 6.447

Review 4.  Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.

Authors:  Jörn Lötsch; Carsten Skarke; Jürgen Liefhold; Gerd Geisslinger
Journal:  Clin Pharmacokinet       Date:  2004       Impact factor: 6.447

5.  Codeine and 6-acetylcodeine analgesia in mice.

Authors:  Steven Milo; Michael Ansonoff; Michael King; Grace C Rossi; Amy Zuckerman; John Pintar; Gavril W Pasternak
Journal:  Cell Mol Neurobiol       Date:  2006-07-26       Impact factor: 5.046

6.  Codeine and clinical impairment in samples in which morphine is not detected.

Authors:  Liliana Bachs; Svetlana Skurtveit; Jørg Mørland
Journal:  Eur J Clin Pharmacol       Date:  2003-03-01       Impact factor: 2.953

7.  Abnormal white matter integrity in chronic users of codeine-containing cough syrups: a tract-based spatial statistics study.

Authors:  Y-W Qiu; H-H Su; X-F Lv; G-H Jiang
Journal:  AJNR Am J Neuroradiol       Date:  2014-08-07       Impact factor: 3.825

Review 8.  Cytochrome P450-activated prodrugs.

Authors:  Paul R Ortiz de Montellano
Journal:  Future Med Chem       Date:  2013-02       Impact factor: 3.808

9.  Short-term UROD treatment on cerebral function in codeine-containing cough syrups dependent male individuals.

Authors:  Ying-Wei Qiu; Gui-Hua Jiang; Huan-Huan Su; Xiao-Fei Lv; Xiao-Fen Ma; Jun-Zhang Tian; Fu-Zhen Zhuo
Journal:  Eur Radiol       Date:  2015-12-10       Impact factor: 5.315

Review 10.  Pain management in patients with cancer: focus on opioid analgesics.

Authors:  Wojciech Leppert
Journal:  Curr Pain Headache Rep       Date:  2011-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.